Following on from Module 1, The Use of Immunotherapy in HCC: Efficacy and Safety, you can now go deeper with your learning in Module 2, The Use of Immunotherapy in HCC: In-depth Subgroup Analyses and Challenges, brought to you by HCC experts Prof. Peter R. Galle and Dr Aiwu Ruth He.

 

In this module, you'll learn about current data and the efficacy and challenges of immunotherapy (IO) for different subgroups of patients with hepatocellular carcinoma (HCC), including how to:

  • Assess liver function using the Albumin-Bilirubin (ALBI) scoring system to evaluate a patient's eligibility for IO treatment
  • Understand the efficacy and safety data in the different subgroups eligible for IO treatment

 

Watch the 4-minute video and download the accompanying slides and flashcard for your reference.

When you're ready to test your knowledge, take the assessment using the blue button beneath the video.

 

Clinical Takeaways

  • The Child-Pugh and ALBI scoring systems are methods to assess liver function

  • There is a need to understand whether specific groups of patients with HCC benefit more from one systemic treatment than another

  • Subgroup analyses in patients with HCC receiving IO and IO combinations show variable hazard ratios across etiologies and liver function. These data are not mature enough to guide treatment decisions

Aiwu Ruth He, MD, PhD is a Professor of Medicine at Columbia University Medical Center. She earned her MD from the Xiangya School of Medicine at Central South University and her PhD in Biochemistry from East Carolina University’s Brody School of Medicine. Dr He completed her postdoctoral training at the National Institutes of Health under the mentorship of Dr Simeon Taylor, followed by an internal medicine residency at the Brody School of Medicine and a Hematology/Oncology fellowship at Georgetown University Hospital.

 

Dr He is a recognized leader in liver cancer research and patient care, with a primary focus on developing innovative therapeutics for hepatocellular carcinoma (HCC) and biliary tract cancer (BTC). 

 

She is deeply committed to a programmatic, multidisciplinary approach to clinical practice, ensuring optimal outcomes for her patients across the continuum of care.

 

Outside of her clinical duties, Dr He serves as the Director of Hepatobiliary Cancers in the Department of Medicine, Division of Hematology and Oncology, as well as the Director of Liver Transplant Oncology at the Center for Liver Disease and Transplantation. In these roles, she oversees clinical research on hepatobiliary cancers.

 

For a list of publications, please visit:

https://pubmed.ncbi.nlm.nih.gov/?term=he%2C+AR+or+He%2C+aiwu

Prof. Aiwu Ruth He has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, BMS, Boston Scientific, Eisai, Genentech and Merck.

Programme summary
Take the micro learning now
Other episodes of this series
The Use of Immunotherapy in HCC

The Use of Immunotherapy in HCC

Module 1: Efficacy and Safety

The Use of Immunotherapy in HCC

The Use of Immunotherapy in HCC

Module 2: In-depth Subgroup Analyses and Challenges

Current Module
The expanding role of immunotherapy in HCC

The expanding role of immunotherapy in HCC

Module 3: Combining locoregional and systemic treatments in intermediate HCC

Share this programme
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Accreditation and Endorsement
EACCME
This course has been accredited by EACCME® for ECMEC®.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
Endorsed by
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar May 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
podcast Podcast
Oncology 
Understanding rare non-small cell lung cancer (NSCLC) alterations

Insights and support for patients

Experts
Dr Joshua Sabari, Debra Montague
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim
animated-video Animated Video
Oncology 
ADCs in HR+/HER2- metastatic breast cancer

Optimising treatment strategies and AE management

Experts
Dr Barbara Pistilli
Endorsed by
GRASP
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.
podcast Podcast

Episode

2

of 2

episode
Oncology 
The HER2 diagnostic and treatment landscape in NSCLC: Episode 2

Navigating common treatment scenarios in HER2-mutant non-small cell lung cancer

Experts
Dr Eric Singhi, Dr Isabel Preeshagul, Oncology Brothers (Moderators)
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 18 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Emerging molecular testing paradigms in NSCLC management

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
animated-video Animated Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer with ESR1-mut tumors

An overview of the EMERALD subgroup analyses

Experts
Prof. Javier Cortés
  • download Downloadable
    Resources
  • clock 8 MIN
  • calendar Apr 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.